Association Between Progression-Free Survival (Pfs) Rate (Pfsr) And Overall Survival (Os) In Lume-Meso, A Study Of Nintedanib (N) Vs. Placebo (P) In Combination With First-Line Pemetrexed/Cisplatin (Pem/Cis) In Patients (Pts) With Malignant Pleural Mesothelioma (Mpm).